Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Autologous mesenchymal stem cell transplantation · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Autologous MSC transplantation | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Autologous mesenchymal stem cell transplantation | BIOLOGICAL | A single IV infusion of up to 2 million cells per kg based on the MSC numbers achieved after culture expansion |
Inclusion Criteria: * Age 18 to 55, inclusive. * Diagnosis of MS * Relapsing form of MS (relapsing-remitting, secondary progressive, or progressive-relapsing course). * EDSS score 3.0-6.5, inclusive. (Must be able to walk) * Active disease during prior 24 months. * Documented evidence of involvemen...
Autologous mesenchymal stem cell transplantation is an investigational cell therapy being studied for Relapsing-Remitting Multiple Sclerosis. It is in Phase 1 clinical development and is not yet approved by the FDA. The therapy uses a patient's own mesenchymal stem cells, which are collected and then transplanted back into the patient.
Autologous mesenchymal stem cell transplantation is being developed by Community Health Systems, Inc., which trades under the ticker CYH. The company is conducting clinical research on this investigational therapy for multiple sclerosis. The therapy is in Phase 1 development and remains investigational.
Autologous mesenchymal stem cell transplantation is in Phase 1 clinical development. It is an investigational therapy for Relapsing-Remitting Multiple Sclerosis and has not been approved by the FDA. The Phase 1 trial has been completed, and the therapy is still in the early stages of clinical testing.
Autologous mesenchymal stem cell transplantation has one completed clinical trial, NCT00813969, titled "Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS." This Phase 1 study enrolled 24 participants in the United States and included patients with Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, and Progressive Relapsing Multiple Sclerosis.
Autologous mesenchymal stem cell transplantation is not FDA approved. It is an investigational therapy currently in Phase 1 clinical development for Relapsing-Remitting Multiple Sclerosis. The therapy has completed a Phase 1 trial but has not yet received regulatory approval for commercial use.